Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) and Eagleford Energy (OTCMKTS:GRUSF – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.
Valuation and Earnings
This table compares Capricor Therapeutics and Eagleford Energy”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Capricor Therapeutics | $22.27 million | 15.11 | -$40.47 million | ($1.64) | -4.49 |
| Eagleford Energy | $27.02 million | 3.47 | -$11.30 million | $0.01 | 45.00 |
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Capricor Therapeutics and Eagleford Energy, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Capricor Therapeutics | 1 | 0 | 7 | 1 | 2.89 |
| Eagleford Energy | 0 | 0 | 0 | 0 | 0.00 |
Capricor Therapeutics presently has a consensus target price of $22.25, indicating a potential upside of 202.31%. Given Capricor Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Capricor Therapeutics is more favorable than Eagleford Energy.
Profitability
This table compares Capricor Therapeutics and Eagleford Energy’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Capricor Therapeutics | N/A | -62.71% | -50.82% |
| Eagleford Energy | 14.90% | 18.13% | 7.82% |
Insider & Institutional Ownership
21.7% of Capricor Therapeutics shares are owned by institutional investors. Comparatively, 9.3% of Eagleford Energy shares are owned by institutional investors. 10.5% of Capricor Therapeutics shares are owned by company insiders. Comparatively, 23.2% of Eagleford Energy shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Eagleford Energy beats Capricor Therapeutics on 8 of the 14 factors compared between the two stocks.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
About Eagleford Energy
Grown Rogue International Inc., together with its subsidiaries, produces and sells cannabis products in the United States. It offers a range of cultivars for consumers, such as indicas, sativas, and hybrids; strain-specific prepackaged flowers; and pre-roll pack products, as well as provides consulting services. The company sells its products through direct-to-retail delivery and third-party delivery, wholesalers, and processors. Grown Rogue International Inc. is headquartered in Medford, Oregon.
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
